American Association for Cancer Research
ccr-23-1763_supplementary_table_s1_suppts1.xlsx (13.22 kB)

Supplementary Table S1 from Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

Download (13.22 kB)
posted on 2024-05-15, 07:23 authored by Patrick G. Pilié, Virginia Giuliani, Wei-Lien Wang, Daniel J. McGrail, Christopher A. Bristow, Natalie Y.L. Ngoi, Keith Kyewalabye, Khalida M. Wani, Hung Le, Erick Campbell, Nora S. Sanchez, Dong Yang, Jinesh S. Gheeya, Rohit Vivek Goswamy, Vijaykumar Holla, Kenna Rael Shaw, Funda Meric-Bernstam, Chiu-Yi Liu, XiaoYan Ma, Ningping Feng, Annette A. Machado, Jennifer P. Bardenhagen, Christopher P. Vellano, Joseph R. Marszalek, Eeson Rajendra, Desiree Piscitello, Timothy I. Johnson, Maria Likhatcheva, Elias Elinati, Jayesh Majithiya, Joana Neves, Vera Grinkevich, Marco Ranzani, Marina Roy Luzarraga, Marie Boursier, Lucy Armstrong, Lerin Geo, Giorgia Lillo, Wai Yiu Tse, Alexander J. Lazar, Scott E. Kopetz, Mary K. Geck Do, Sarah Lively, Michael G. Johnson, Helen M.R. Robinson, Graeme C.M. Smith, Christopher L. Carroll, M. Emilia Di Francesco, Philip Jones, Timothy P. Heffernan, Timothy A. Yap

Supplementary Table S1


National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

Cancer Prevention and Research Institute of Texas (CPRIT)

Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (Khalifa Institute)

U.S. Department of Defense (DOD)

V Foundation for Cancer Research (VFCR)

Conquer Cancer Foundation (CCF)



Mutations in the ATM gene are common in multiple cancers, but clinical studies of therapies targeting ATM-aberrant cancers have yielded mixed results. Refinement of ATM loss of function (LOF) as a predictive biomarker of response is urgently needed. We present the first disclosure and preclinical development of a novel, selective ATR inhibitor, ART0380, and test its antitumor activity in multiple preclinical cancer models. To refine ATM LOF as a predictive biomarker, we performed a comprehensive pan-cancer analysis of ATM variants in patient tumors and then assessed the ATM variant-to-protein relationship. Finally, we assessed a novel ATM LOF biomarker approach in retrospective clinical data sets of patients treated with platinum-based chemotherapy or ATR inhibition. ART0380 had potent, selective antitumor activity in a range of preclinical cancer models with differing degrees of ATM LOF. Pan-cancer analysis identified 10,609 ATM variants in 8,587 patient tumors. Cancer lineage–specific differences were seen in the prevalence of deleterious (Tier 1) versus unknown/benign (Tier 2) variants, selective pressure for loss of heterozygosity, and concordance between a deleterious variant and ATM loss of protein (LOP). A novel ATM LOF biomarker approach that accounts for variant classification, relationship to ATM LOP, and tissue-specific penetrance significantly enriched for patients who benefited from platinum-based chemotherapy or ATR inhibition. These data help to better define ATM LOF across tumor types in order to optimize patient selection and improve molecularly targeted therapeutic approaches for patients with ATM LOF cancers.

Usage metrics

    Clinical Cancer Research



    Ref. manager